Treatment with the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ resulted in patients with persistent atrial fibrillation experiencing an improved quality of life The catheter is part of Abbott’s suite of electrophysiology solutions designed to improve procedures to address cardiac arrythmias ABBOTT PARK, Ill., April 29, 2022 /PRNewswire/ — Abbott (NYSE: ABT) today […]

ABBOTT PARK, Ill., Jan. 21, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, a new ablation catheter designed to help physicians accurately and effectively treat atrial fibrillation (AFib). The approval further expands Abbott’s portfolio of cardiac ablation tools that integrate […]